The Epothilones: How Pharmacology Relates to Clinical Utility

Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)

(2017) A. K. Conlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061

(2017) R. Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study

(2017) L. E. Abrey et al.   JOURNAL OF CLINICAL ONCOLOGY

Ixabepilone (BMS-247550) and metastatic renal cell carcinoma (mRCC)

(2017) H. Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy

(2017) A. L. Harzstark et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC)

(2017) J. Graff et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

(2017) K. N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma

(2017) D. Wenk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children’s Oncology Group

(2017) S. Jacobs et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study evaluating systemic sagopilone (ZK-EPO) treatment in patients with recurrent malignant gliomas

(2017) A. Silvani et al.   JOURNAL OF CLINICAL ONCOLOGY

A population pharmacokinetic analysis of ixabepilone in patients with cancer

(2017) M. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Sagopilone

(2009) E.J. Alexander et al.   DRUGS OF THE FUTURE

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

(2008) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

(2008) William Schelman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

(2008) Francis Y. F. Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo

(2008) Terence O’Reilly et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone

(2008) J. Hoffmann et al.   CANCER RESEARCH

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate

(2008) Ulrich Klar et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer

(2008) Meghana Trivedi et al.   Future Oncology